Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Outcomes After Acute Coronary Syndrome in Patients With Diabetes Mellitus and Peripheral Artery Disease (from the TRACER, TRILOGY-ACS, APPRAISE-2, and PLATO Clinical Trials)

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  1. Health Literacy and Risk Factors for Coronary Artery Disease (From the CONCARDPCI Study)

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  2. Comparison of Outcome in Patients With Familial Versus Spontaneous Atrial Septal Defect

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  3. Mitral Valve Infective Endocarditis after Trans-Catheter Aortic Valve Implantation

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  1. Major adverse cardiovascular events following acute coronary syndrome in patients with bipolar disorder

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  • Rubina Attar
  • Angie Wu
  • Daniel Wojdyla
  • Svend Eggert Jensen
  • Pontus Andell
  • Kenneth W Mahaffey
  • Matthew T Roe
  • Stefan K James
  • Lars Wallentin
  • Sreekanth Vemulapalli
  • John H Alexander
  • Renato D Lopes
  • E Magnus Ohman
  • Adrian F Hernandez
  • Manesh R Patel
  • W Schuyler Jones
Vis graf over relationer

Patients with acute coronary syndrome (ACS) are at risk for recurrent adverse events, and multiple reports suggest that this risk is increased in patients with concomitant diabetes mellitus (DM) and peripheral artery disease (PAD). The aim of this article was to investigate cardiovascular outcomes in patients with DM presenting with ACS, stratified by PAD status. Data were derived from 4 randomized post-ACS trials (PLATO [Platelet Inhibition and Patient Outcomes], APPRAISE-2 p Apixaban for Prevention of Acute Ischemic Events 2], TRILOGY [Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage], and TRACER [Thrombin Receptor Agonist for Clinical Event Reduction in Acute Coronary Syndrome]). Using Cox regression analysis, we investigated major adverse cardiovascular events (MACEs), a composite of cardiovascular mortality, myocardial infarction (MI), or stroke and the individual components of MACE and all-cause mortality in patients with DM, presenting with ACS, stratified by PAD status as the risk modifier. This study included 15,387 patients with a diagnosis of DM and ACS, of whom 1,751 had an additional diagnosis of PAD. PAD was associated with more than doubled rates of MACE (hazard ratio [HR] 2.03, 95% confidence interval [CI] 1.81 to 2.27), all-cause mortality (HR 2.48, 95% CI 2.14 to 2.87), cardiovascular mortality (HR 2.42, 95% CI 2.04 to 2.86), and MI (HR 2.07, 95% CI 1.79 to 2.38). Patients with both PAD and DM were also more optimally treated with antihypertensive, antidiabetic, and statin medication at baseline. In conclusion, this analysis of 4 major post-ACS trials showed that patients with DM and PAD had a substantially higher risk of MACE, cardiovascular mortality, all-cause mortality, and MI despite being optimally treated with guideline-based therapies.

TidsskriftThe American journal of cardiology
Sider (fra-til)11-17
Antal sider7
StatusUdgivet - 1 sep. 2022

Bibliografisk note

Copyright © 2022 Elsevier Inc. All rights reserved.

ID: 79468984